Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Argenx SE
  6. News
  7. Summary
    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Argenx : Swings to H1 Earnings as Revenue Jumps From Last Year

07/29/2021 | 07:59am EDT


ę MT Newswires 2021
All news about ARGENX SE
10/08ARGENX : argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upco..
PU
10/08ARGENX : to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Ne..
GL
10/08argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming N..
GL
10/07ARGENX : Jefferies Starts argenx at Buy with $362 Price Target
MT
09/24European ADRs Move Lower in Friday Trading
MT
09/23ARGENX : Redburn Upgrades argenx to Buy From Neutral
MT
09/20ARGENX SE(ENXTBR : ARGX) dropped from S&P Global BMI Index
CI
09/20ARGENX SE(NASDAQGS : ARGX) added to S&P Global BMI Index
CI
09/07ARGENX : Morgan Stanley Downgrades argenx SE to Equalweight from Overweight, Adjusts Price..
MT
09/03ARGENX : to Present at Upcoming Investor Conferences
AQ
More news
Analyst Recommendations on ARGENX SE
More recommendations
Financials
Sales 2021 442 M 512 M 512 M
Net income 2021 -346 M -401 M -401 M
Net cash 2021 1 058 M 1 227 M 1 227 M
P/E ratio 2021 -37,8x
Yield 2021 -
Capitalization 13 152 M 15 257 M 15 256 M
EV / Sales 2021 27,4x
EV / Sales 2022 60,2x
Nbr of Employees 336
Free-Float 99,1%
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | ARGX | NL0010832176 | MarketScreener
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 255,30 €
Average target price 323,12 €
Spread / Average Target 26,6%
EPS Revisions
Managers and Directors
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Karl Gubitz Chief Financial Officer
Peter K. M. Verhaeghe Chairman
Hans J. W. de Haard Chief Scientific Officer
Wim Parys Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ARGENX SE5.50%15 257
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156